InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.33
(
-0.07%
)
US TECH 100
19,244.46
(
-0.07%
)
Dow Jones
39,167.61
(
0.08%
)
Brent Oil
85.01
(
0.00%
)
Bitcoin
64,063.25
(
-1.17%
)
Post# of 252286
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119888
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 215055

Wednesday, 11/15/2017 7:08:26 PM

Wednesday, November 15, 2017 7:08:26 PM

Post# of 252286
NKTR—18 patients are already enrolled (at MSKCC and MD Anderson) in the IST testing Opdivo + NKTR-214 in second-line sarcomas, an area with a very high unmet need. (Slide #63 from the SITC slide deck says “proposed phase-2 study,” but the trial has already started, according to the webcast narrative.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up